;PMID: 10448061
;source_file_848.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..52] = [t:0..52]
;1)sentence:[e:58..121] = [t:58..121]
;2)section:[e:125..156] = [t:125..156]
;3)section:[e:160..245] = [t:160..245]
;4)sentence:[e:249..461] = [t:249..461]
;5)sentence:[e:462..757] = [t:462..757]
;6)sentence:[e:758..889] = [t:758..889]
;7)sentence:[e:890..1094] = [t:890..1094]
;8)sentence:[e:1095..1221] = [t:1095..1221]
;9)sentence:[e:1222..1294] = [t:1222..1294]
;10)sentence:[e:1295..1387] = [t:1295..1387]
;11)sentence:[e:1388..1591] = [t:1388..1591]
;12)sentence:[e:1592..1755] = [t:1592..1755]
;13)section:[e:1757..1787] = [t:1757..1787]
;14)section:[e:1791..1836] = [t:1791..1836]

;section 0 Span:0..52
;Biochem Biophys Res Commun. 1999 Aug 19;262(1):20-4.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res)
        (NNP:[20..26] Commun) (,:[26..27] .) (CD:[28..32] 1999)
        (NNP:[33..36] Aug) (CD:[37..44] 19;262-LRB-) (CD:[44..45] 1)
        (-RRB-:[45..46] -RRB-) (CD:[46..49] :20) (::[49..50] -) (CD:[50..52] 4.)))

;sentence 1 Span:58..121
;Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
;[58..69]:substance:"Resveratrol"
;[91..110]:cyp450:"cytochrome P450 1A1"
;[111..120]:substance:"inhibitor"
(SENT
  (S-HLN
    (NP-SBJ (NN:[58..69] Resveratrol))
    (VP (VBZ:[70..72] is)
      (NP-PRD (DT:[73..74] a) (JJ:[75..84] selective)
        (NML (JJ:[85..90] human)
          
          (NML (NN:[91..101] cytochrome) (NN:[102..106] P450))
          (NN:[107..110] 1A1))
        (NN:[111..120] inhibitor)))
    (.:[120..121] .)))

;section 2 Span:125..156
;Chun YJ, Kim MY, Guengerich FP.
(SEC
  (FRAG (NNP:[125..129] Chun) (NNP:[130..132] YJ) (,:[132..133] ,)
        (NNP:[134..137] Kim) (NNP:[138..140] MY) (,:[140..141] ,)
        (NNP:[142..152] Guengerich) (NNP:[153..155] FP) (.:[155..156] .)))

;section 3 Span:160..245
;College of Pharmacy, Chungang University, Seoul, Korea, 156-756. 
;yjchun@chungang.edu
(SEC
  (FRAG (NNP:[160..167] College) (IN:[168..170] of) (NNP:[171..179] Pharmacy)
        (,:[179..180] ,) (NNP:[181..189] Chungang) (NNP:[190..200] University)
        (,:[200..201] ,) (NNP:[202..207] Seoul) (,:[207..208] ,)
        (NNP:[209..214] Korea) (,:[214..215] ,) (CD:[216..219] 156)
        (::[219..220] -) (CD:[220..223] 756) (.:[223..224] .)
        (-RRB-:[226..241] yjchun@chungang) (.:[241..245] .edu)))

;sentence 4 Span:249..461
;Resveratrol (trans-3,4',5-trihydroxystilbene) is a phytoalexin compound found
;in  juice and wine produced from dark-skinned grape cultivars and reported to
;have  anti-inflammatory and anticarcinogenic activities.
;[249..260]:substance:"Resveratrol"
;[262..293]:substance:"trans-3,4',5-trihydroxystilbene"
;[300..320]:substance:"phytoalexin compound"
;[331..336]:substance:"juice"
;[341..345]:substance:"wine"
(SENT
  (S
    (NP-SBJ-2 (NN:[249..260] Resveratrol)
      (PRN (-LRB-:[261..262] -LRB-)
        (NP (NN:[262..293] trans-3,4',5-trihydroxystilbene))
        (-RRB-:[293..294] -RRB-)))
    (VP (VBZ:[295..297] is)
      (NP-PRD
        (NP (DT:[298..299] a)
           (NN:[300..311] phytoalexin) (NN:[312..320] compound))
        (VP
          (VP (VBN:[321..326] found)
            (NP (-NONE-:[326..326] *))
            (PP-LOC (IN:[327..329] in)
              (NP
                (NP (NN:[331..336] juice) (CC:[337..340] and)
                    (NN:[341..345] wine))
                (VP (VBN:[346..354] produced)
                  (NP (-NONE-:[354..354] *))
                  (PP-CLR (IN:[355..359] from)
                    (NP (JJ:[360..372] dark-skinned) (NN:[373..378] grape)
                        (NNS:[379..388] cultivars)))))))
          (CC:[389..392] and)
          (VP (VBN:[393..401] reported)
            (S
              (NP-SBJ-2 (-NONE-:[401..401] *))
              (VP (TO:[402..404] to)
                (VP (VB:[405..409] have)
                  (NP
                    (NP
                      (ADJP (AFX:[411..415] anti) (HYPH:[415..416] -)
                            (JJ:[416..428] inflammatory))
                      (NML-1 (-NONE-:[428..428] *P*)))
                    (CC:[429..432] and)
                    (NP (JJ:[433..449] anticarcinogenic)
                      (NML-1 (NNS:[450..460] activities)))))))))))
    (.:[460..461] .)))

;sentence 5 Span:462..757
;To investigate the mechanism  of anticarcinogenic activities of resveratrol,
;the effects on cytochrome P450  (P450) were determined in human liver
;microsomes and Escherichia coli membranes  coexpressing human P450 1A1 or
;P450 1A2 with human NADPH-P450 reductase  (bicistronic expression system).
;[526..537]:substance:"resveratrol"
;[554..569]:cyp450:"cytochrome P450"
;[572..576]:cyp450:"P450"
;[671..679]:cyp450:"P450 1A1"
;[683..691]:cyp450:"P450 1A2"
;[703..723]:substance:"NADPH-P450 reductase"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[462..462] *))
      (VP (TO:[462..464] To)
        (VP (VB:[465..476] investigate)
          (NP
            (NP (DT:[477..480] the) (NN:[481..490] mechanism))
            (PP (IN:[492..494] of)
              (NP
                (NP (JJ:[495..511] anticarcinogenic) (NNS:[512..522] activities))
                (PP (IN:[523..525] of)
                  (NP (NN:[526..537] resveratrol)))))))))
    (,:[537..538] ,)
    (NP-SBJ-2
      (NP (DT:[539..542] the) (NNS:[543..550] effects))
      (PP (IN:[551..553] on)
        (NP
          (NP (NN:[554..564] cytochrome) (NN:[565..569] P450))
          (NP (-LRB-:[571..572] -LRB-) (NN:[572..576] P450)
              (-RRB-:[576..577] -RRB-)))))
    (VP (VBD:[578..582] were)
      (VP (VBN:[583..593] determined)
        (NP-2 (-NONE-:[593..593] *))
        (PP-LOC (IN:[594..596] in)
          (NP
            (NP
              (NP (JJ:[597..602] human) (NN:[603..608] liver)
                  (NNS:[609..619] microsomes))
              (CC:[620..623] and)
              (NP
                (NML (NNP:[624..635] Escherichia) (NNP:[636..640] coli))
                (NNS:[641..650] membranes)))
            (VP (VBG:[652..664] coexpressing)
              (NP
                (NP
                  (ADJP-1 (JJ:[665..670] human))
                   (NN:[671..675] P450) (NN:[676..679] 1A1))
                (CC:[680..682] or)
                (NP
                  (ADJP-1 (-NONE-:[682..682] *P*))
                   (NN:[683..687] P450) (NN:[688..691] 1A2)))
              (PP-CLR (IN:[692..696] with)
                (NP (JJ:[697..702] human)
                  
                  (NP (NN:[703..708] NADPH) (HYPH:[708..709] -)
                      (NN:[709..713] P450))
                  (NN:[714..723] reductase)
                  (PRN (-LRB-:[725..726] -LRB-)
                    (NP (JJ:[726..737] bicistronic) (NN:[738..748] expression)
                        (NN:[749..755] system))
                    (-RRB-:[755..756] -RRB-)))))))))
    (.:[756..757] .)))

;sentence 6 Span:758..889
;Resveratrol slightly inhibited ethoxyresorufin  O-deethylation (EROD)
;activity in human liver microsomes with an IC(50) of 1.1  mM.
;[758..769]:substance:"Resveratrol"
;[789..804]:substance:"ethoxyresorufin"
;[871..877]:quantitative-name:"IC(50)"
;[881..884]:quantitative-value:"1.1"
;[886..888]:quantitative-units:"mM"
(SENT
  (S
    (NP-SBJ (NN:[758..769] Resveratrol))
    (VP
      (ADVP (RB:[770..778] slightly))
      (VBD:[779..788] inhibited)
      (NP
        (NML
          (NML (NN:[789..804] ethoxyresorufin) (NN:[806..807] O)
               (HYPH:[807..808] -) (NN:[808..820] deethylation))
          (NML (-LRB-:[821..822] -LRB-) (NN:[822..826] EROD)
               (-RRB-:[826..827] -RRB-)))
        (NN:[828..836] activity))
      (PP-LOC (IN:[837..839] in)
        (NP (JJ:[840..845] human) (NN:[846..851] liver)
            (NNS:[852..862] microsomes)))
      (PP (IN:[863..867] with)
        (NP
          (NP (DT:[868..870] an) (NN:[871..877] IC-LRB-50-RRB-))
          (PP (IN:[878..880] of)
            (NP (CD:[881..884] 1.1) (NN:[886..888] mM))))))
    (.:[888..889] .)))

;sentence 7 Span:890..1094
;Interestingly, resveratrol exhibited potent inhibition of human P450 1A1 in 
;a dose-dependent manner with IC(50) of 23 microM for EROD and IC(50) of 11 
;microM for methoxyresorufin O-demethylation (MROD).
;[905..916]:substance:"resveratrol"
;[954..962]:cyp450:"P450 1A1"
;[996..1002]:quantitative-name:"IC(50)"
;[1006..1008]:quantitative-value:"23"
;[1009..1015]:quantitative-units:"microM"
;[1029..1035]:quantitative-name:"IC(50)"
;[1039..1041]:quantitative-value:"11"
;[1043..1049]:quantitative-units:"microM"
;[1054..1070]:substance:"methoxyresorufin"
(SENT
  (S
    (ADVP (RB:[890..903] Interestingly))
    (,:[903..904] ,)
    (NP-SBJ (NN:[905..916] resveratrol))
    (VP (VBD:[917..926] exhibited)
      (NP
        (NP (JJ:[927..933] potent) (NN:[934..944] inhibition))
        (PP (IN:[945..947] of)
          (NP (JJ:[948..953] human)
             (NN:[954..958] P450) (NN:[959..962] 1A1))))
      (PP-MNR (IN:[963..965] in)
        (NP (DT:[967..968] a)
          (ADJP (NN:[969..973] dose) (HYPH:[973..974] -)
                (JJ:[974..983] dependent))
          (NN:[984..990] manner)))
      (PP (IN:[991..995] with)
        (NP
          (NP
            (NP (NN:[996..1002] IC-LRB-50-RRB-))
            (PP (IN:[1003..1005] of)
              (NP (CD:[1006..1008] 23) (NN:[1009..1015] microM)))
            (PP (IN:[1016..1019] for)
              (NP (NN:[1020..1024] EROD))))
          (CC:[1025..1028] and)
          (NP
            (NP (NN:[1029..1035] IC-LRB-50-RRB-))
            (PP (IN:[1036..1038] of)
              (NP (CD:[1039..1041] 11) (NN:[1043..1049] microM)))
            (PP (IN:[1050..1053] for)
              (NP
                (NP (NN:[1054..1070] methoxyresorufin) (NN:[1071..1072] O)
                    (HYPH:[1072..1073] -) (NN:[1073..1086] demethylation))
                (NP (-LRB-:[1087..1088] -LRB-) (NN:[1088..1092] MROD)
                    (-RRB-:[1092..1093] -RRB-))))))))
    (.:[1093..1094] .)))

;sentence 8 Span:1095..1221
;However, the inhibition of  human P450 1A2 by resveratrol was not so strong
;(IC(50) 1.2 mM for EROD and 580  microM for MROD).
;[1129..1137]:cyp450:"P450 1A2"
;[1141..1152]:substance:"resveratrol"
;[1172..1178]:quantitative-name:"IC(50)"
;[1179..1182]:quantitative-value:"1.2"
;[1183..1185]:quantitative-units:"mM"
;[1199..1202]:quantitative-value:"580"
;[1204..1210]:quantitative-units:"microM"
(SENT
  (S
    (ADVP (RB:[1095..1102] However))
    (,:[1102..1103] ,)
    (NP-SBJ
      (NP (DT:[1104..1107] the) (NN:[1108..1118] inhibition))
      (PP (IN:[1119..1121] of)
        (NP (JJ:[1123..1128] human)
           (NN:[1129..1133] P450) (NN:[1134..1137] 1A2)))
      (PP (IN:[1138..1140] by)
        (NP (NN:[1141..1152] resveratrol))))
    (VP (VBD:[1153..1156] was) (RB:[1157..1160] not)
      (ADJP-PRD (RB:[1161..1163] so) (JJ:[1164..1170] strong))
      (PRN (-LRB-:[1171..1172] -LRB-)
        (S
          (NP-SBJ (NN:[1172..1178] IC-LRB-50-RRB-))
          (NP-PRD
            (NP
              (NP (CD:[1179..1182] 1.2) (NN:[1183..1185] mM))
              (PP (IN:[1186..1189] for)
                (NP (NN:[1190..1194] EROD))))
            (CC:[1195..1198] and)
            (NP
              (NP (CD:[1199..1202] 580) (NN:[1204..1210] microM))
              (PP (IN:[1211..1214] for)
                (NP (NN:[1215..1219] MROD))))))
        (-RRB-:[1219..1220] -RRB-)))
    (.:[1220..1221] .)))

;sentence 9 Span:1222..1294
;Resveratrol showed over 50-fold selectivity for P450 1A1 over  P450 1A2.
;[1222..1233]:substance:"Resveratrol"
;[1246..1253]:quantitative-value:"50-fold"
;[1270..1278]:cyp450:"P450 1A1"
;[1285..1293]:cyp450:"P450 1A2"
(SENT
  (S
    (NP-SBJ (NN:[1222..1233] Resveratrol))
    (VP (VBD:[1234..1240] showed)
      (NP
        (ADJP-EXT
          (QP (IN:[1241..1245] over) (CD:[1246..1248] 50))
          (HYPH:[1248..1249] -) (JJ:[1249..1253] fold))
        (NN:[1254..1265] selectivity))
      (PP (IN:[1266..1269] for)
        (NP (NN:[1270..1274] P450) (NN:[1275..1278] 1A1)))
      (PP (IN:[1279..1283] over)
        (NP (NN:[1285..1289] P450) (NN:[1290..1293] 1A2))))
    (.:[1293..1294] .)))

;sentence 10 Span:1295..1387
;The activities of human NADPH-P450 reductase were not significantly  changed
;by resveratrol.
;[1319..1339]:substance:"NADPH-P450 reductase"
;[1375..1386]:substance:"resveratrol"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1295..1298] The) (NNS:[1299..1309] activities))
      (PP (IN:[1310..1312] of)
        (NP (JJ:[1313..1318] human)
          
          (NML (NN:[1319..1324] NADPH) (HYPH:[1324..1325] -)
               (NN:[1325..1329] P450))
          (NN:[1330..1339] reductase))))
    (VP (VBD:[1340..1344] were) (RB:[1345..1348] not)
      (VP
        (ADVP (RB:[1349..1362] significantly))
        (VBN:[1364..1371] changed)
        (NP-1 (-NONE-:[1371..1371] *))
        (PP-LGS (IN:[1372..1374] by)
          (NP (NN:[1375..1386] resveratrol)))))
    (.:[1386..1387] .)))

;sentence 11 Span:1388..1591
;In a human P450 1A1/reductase bicistronic expression  system, resveratrol
;inhibited human P450 1A1 activity in a mixed-type inhibition 
;(competitive-noncompetitive) with a K(i) values of 9 and 89 microM.
;[1399..1407]:cyp450:"P450 1A1"
;[1408..1417]:substance:"reductase"
;[1450..1461]:substance:"resveratrol"
;[1478..1486]:cyp450:"P450 1A1"
;[1560..1564]:quantitative-name:"K(i)"
;[1575..1576]:quantitative-value:"9"
;[1581..1583]:quantitative-value:"89"
;[1584..1590]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[1388..1390] In)
      (NP (DT:[1391..1392] a)
        (NML
          (NML (JJ:[1393..1398] human)
             (NN:[1399..1403] P450) (NN:[1404..1407] 1A1))
          (SYM:[1407..1408] /)
          (NML (NN:[1408..1417] reductase) (JJ:[1418..1429] bicistronic)
               (NN:[1430..1440] expression)))
        (NN:[1442..1448] system)))
    (,:[1448..1449] ,)
    (NP-SBJ (NN:[1450..1461] resveratrol))
    (VP (VBD:[1462..1471] inhibited)
      (NP
        (NML (JJ:[1472..1477] human)
           (NN:[1478..1482] P450) (NN:[1483..1486] 1A1))
        (NN:[1487..1495] activity))
      (PP-LOC (IN:[1496..1498] in)
        (PRN
          (NP (DT:[1499..1500] a) (JJ:[1501..1511] mixed-type)
              (NN:[1512..1522] inhibition)
            (PRN (-LRB-:[1524..1525] -LRB-)
              (ADJP (JJ:[1525..1536] competitive) (HYPH:[1536..1537] -)
                    (JJ:[1537..1551] noncompetitive))
              (-RRB-:[1551..1552] -RRB-)))
          (PP (IN:[1553..1557] with)
            (NP
              (NP (DT:[1558..1559] a) (NN:[1560..1564] K-LRB-i-RRB-)
                  (NNS:[1565..1571] values))
              (PP (IN:[1572..1574] of)
                (NP
                  (NP (CD:[1575..1576] 9)
                    (NML-1 (-NONE-:[1576..1576] *P*)))
                  (CC:[1577..1580] and)
                  (NP (CD:[1581..1583] 89)
                    (NML-1 (NN:[1584..1590] microM))))))))))
    (.:[1590..1591] .)))

;sentence 12 Span:1592..1755
;These  results suggest that resveratrol is a selective human P450 1A1
;inhibitor, and  may be considered for use as a strong cancer chemopreventive
;agent in humans.
;[1620..1631]:substance:"resveratrol"
;[1653..1661]:cyp450:"P450 1A1"
;[1662..1671]:substance:"inhibitor"
;[1739..1744]:substance:"agent"
(SENT
  (S
    (NP-SBJ (DT:[1592..1597] These) (NNS:[1599..1606] results))
    (VP (VBP:[1607..1614] suggest)
      (SBAR (IN:[1615..1619] that)
        (S
          (NP-SBJ-1 (NN:[1620..1631] resveratrol))
          (VP
            (VP (VBZ:[1632..1634] is)
              (NP-PRD (DT:[1635..1636] a) (JJ:[1637..1646] selective)
                (NML (JJ:[1647..1652] human)
                   (NN:[1653..1657] P450) (NN:[1658..1661] 1A1))
                (NN:[1662..1671] inhibitor)))
            (,:[1671..1672] ,) (CC:[1673..1676] and)
            (VP (MD:[1678..1681] may)
              (VP (VB:[1682..1684] be)
                (VP (VBN:[1685..1695] considered)
                  (NP-1 (-NONE-:[1695..1695] *))
                  (PP (IN:[1696..1699] for)
                    (NP
                      (NP (NN:[1700..1703] use))
                      (PP (IN:[1704..1706] as)
                        (NP (DT:[1707..1708] a) (JJ:[1709..1715] strong)
                          (ADJP (NN:[1716..1722] cancer)
                                (JJ:[1723..1738] chemopreventive))
                          (NN:[1739..1744] agent)))
                      (PP-LOC (IN:[1745..1747] in)
                        (NP (NNS:[1748..1754] humans))))))))))))
    (.:[1754..1755] .)))

;section 13 Span:1757..1787
;Copyright 1999 Academic Press.
(SEC
  (FRAG (NN:[1757..1766] Copyright) (CD:[1767..1771] 1999)
        (NNP:[1772..1780] Academic) (NNP:[1781..1786] Press) (.:[1786..1787] .)))

;section 14 Span:1791..1836
;PMID: 10448061 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1791..1795] PMID) (::[1795..1796] :) (CD:[1797..1805] 10448061)
        (NN:[1806..1807] -LSB-) (NNP:[1807..1813] PubMed) (::[1814..1815] -)
        (NN:[1816..1823] indexed) (IN:[1824..1827] for)
        (NNP:[1828..1836] MEDLINE-RSB-)))
